Kelly: Ginkgo operates a 300,000-square-foot robotic data lab
Jason Kelly · No Priors Ep. 34 | With Ginkgo Bioworks Co-Founder and CEO Jason Kelly · Sep 28, 2023 · at 19:38
Ginkgo Bioworks CEO Jason Kelly responds to Sarah Guo's question about the source of Ginkgo's proprietary biological AI training data.
0:00 / 0:10exact quote · 10.0s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Yeah, we have a 300,000 square foot robotic lab that they built in the last 10 years, and so we generate that, and we do it in service of our customer projects, we can do our own data generation, but yeah, that's where it comes from.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Jason Kelly
Kelly: AI will outperform humans in biology faster than in English
“And so I feel like these computer brains are going to kick our ass a lot faster in this domain than they do in English.”
Kelly: AI biosecurity lone-actor risk is low due to data scarcity
“The idea that, like, we know how to, like, exactly, like, design for that sort of thing is low. You could try something, but it's not like, oh, I know for sure it's just someone's waiting to do it. Remember, you need data. It's hard to accumulate that. Yeah, i…”
Kelly: Ginkgo gives 10x super-voting shares to all active employees
“At Ginkgo, we took this Silicon Valley idea of founder super voting shares and extended it to the entire employee base. So it's not just us, anyone who's at the company, and it goes away if you leave, ah, gets 10 X voting for their B shares versus the A shares…”
Kelly: Neural Network Analysis Will Function Like Systems Biology
“Like you're about to experience, like the analysis of these neural nets is going to look like systems biology, right? It's going to be like, go in and like, try to back, figure out a thing that you didn't design, my friends.”
Kelly: Major biotech and pharma companies remain fully vertically integrated
“Where's the fast platforms? Like, where's all the horizontal stuff? Where's the operating systems? And it's like nowhere, like vertical integration, Merck, Pfizer, Bayer, Syngenta, like every one of these companies is like its own tech stack top to bottom, you…”